Cargando…

Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study

PURPOSE: Real‐world data from large administrative claims databases in Japan have recently become available, but limited evidence exists to support their validity. VALIDATE‐J validated claims‐based algorithms for selected cancers in Japan. METHODS: VALIDATE‐J was a multicenter, cross‐sectional, retr...

Descripción completa

Detalles Bibliográficos
Autores principales: de Luise, Cynthia, Sugiyama, Naonobu, Morishima, Toshitaka, Higuchi, Takakazu, Katayama, Kayoko, Nakamura, Sho, Chen, Haoqian, Nonnenmacher, Edward, Hase, Ryota, Jinno, Sadao, Kinjo, Mitsuyo, Suzuki, Daisuke, Tanaka, Yoshiya, Setoguchi, Soko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453514/
https://www.ncbi.nlm.nih.gov/pubmed/33960542
http://dx.doi.org/10.1002/pds.5263
_version_ 1784570288880484352
author de Luise, Cynthia
Sugiyama, Naonobu
Morishima, Toshitaka
Higuchi, Takakazu
Katayama, Kayoko
Nakamura, Sho
Chen, Haoqian
Nonnenmacher, Edward
Hase, Ryota
Jinno, Sadao
Kinjo, Mitsuyo
Suzuki, Daisuke
Tanaka, Yoshiya
Setoguchi, Soko
author_facet de Luise, Cynthia
Sugiyama, Naonobu
Morishima, Toshitaka
Higuchi, Takakazu
Katayama, Kayoko
Nakamura, Sho
Chen, Haoqian
Nonnenmacher, Edward
Hase, Ryota
Jinno, Sadao
Kinjo, Mitsuyo
Suzuki, Daisuke
Tanaka, Yoshiya
Setoguchi, Soko
author_sort de Luise, Cynthia
collection PubMed
description PURPOSE: Real‐world data from large administrative claims databases in Japan have recently become available, but limited evidence exists to support their validity. VALIDATE‐J validated claims‐based algorithms for selected cancers in Japan. METHODS: VALIDATE‐J was a multicenter, cross‐sectional, retrospective study. Disease‐identifying algorithms were used to identify cancers diagnosed between January or March 2012 and December 2016 using claims data from two hospitals in Japan. Positive predictive values (PPVs), specificity, and sensitivity were calculated for prevalent (regardless of baseline cancer‐free period) and incident (12‐month cancer‐free period; with claims and registry periods in the same month) cases, using hospital cancer registry data as gold standard. RESULTS: 22 108 cancers were identified in the hospital claims databases. PPVs (number of registry cases) for prevalent/incident cases were: any malignancy 79.0% (25 934)/73.1% (18 119); colorectal 84.4% (3519)/65.6% (2340); gastric 87.4% (3534)/76.8% (2279); lung 88.1% (2066)/79.9% (1636); breast 86.4% (4959)/59.9% (3185); pancreatic 87.1% (582)/80.4% (508); melanoma 48.7% (46)/42.9% (36); and lymphoma 83.6% (1457)/77.8% (1035). Specificity ranged from 98.3% to 100% (prevalent)/99.5% to 100% (incident); sensitivity ranged from 39.1% to 67.6% (prevalent)/12.5% to 31.4% (incident). PPVs of claims‐based algorithms for several cancers in patients ≥66 years of age were slightly higher than those in a US Medicare population. CONCLUSIONS: VALIDATE‐J demonstrated high specificity and modest‐to‐moderate sensitivity for claims‐based algorithms of most malignancies using Japanese claims data. Use of claims‐based algorithms will enable identification of patient populations from claims databases, while avoiding direct patient identification. Further research is needed to confirm the generalizability of our results and applicability to specific subgroups of patient populations.
format Online
Article
Text
id pubmed-8453514
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-84535142021-09-27 Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study de Luise, Cynthia Sugiyama, Naonobu Morishima, Toshitaka Higuchi, Takakazu Katayama, Kayoko Nakamura, Sho Chen, Haoqian Nonnenmacher, Edward Hase, Ryota Jinno, Sadao Kinjo, Mitsuyo Suzuki, Daisuke Tanaka, Yoshiya Setoguchi, Soko Pharmacoepidemiol Drug Saf Original Articles PURPOSE: Real‐world data from large administrative claims databases in Japan have recently become available, but limited evidence exists to support their validity. VALIDATE‐J validated claims‐based algorithms for selected cancers in Japan. METHODS: VALIDATE‐J was a multicenter, cross‐sectional, retrospective study. Disease‐identifying algorithms were used to identify cancers diagnosed between January or March 2012 and December 2016 using claims data from two hospitals in Japan. Positive predictive values (PPVs), specificity, and sensitivity were calculated for prevalent (regardless of baseline cancer‐free period) and incident (12‐month cancer‐free period; with claims and registry periods in the same month) cases, using hospital cancer registry data as gold standard. RESULTS: 22 108 cancers were identified in the hospital claims databases. PPVs (number of registry cases) for prevalent/incident cases were: any malignancy 79.0% (25 934)/73.1% (18 119); colorectal 84.4% (3519)/65.6% (2340); gastric 87.4% (3534)/76.8% (2279); lung 88.1% (2066)/79.9% (1636); breast 86.4% (4959)/59.9% (3185); pancreatic 87.1% (582)/80.4% (508); melanoma 48.7% (46)/42.9% (36); and lymphoma 83.6% (1457)/77.8% (1035). Specificity ranged from 98.3% to 100% (prevalent)/99.5% to 100% (incident); sensitivity ranged from 39.1% to 67.6% (prevalent)/12.5% to 31.4% (incident). PPVs of claims‐based algorithms for several cancers in patients ≥66 years of age were slightly higher than those in a US Medicare population. CONCLUSIONS: VALIDATE‐J demonstrated high specificity and modest‐to‐moderate sensitivity for claims‐based algorithms of most malignancies using Japanese claims data. Use of claims‐based algorithms will enable identification of patient populations from claims databases, while avoiding direct patient identification. Further research is needed to confirm the generalizability of our results and applicability to specific subgroups of patient populations. John Wiley & Sons, Inc. 2021-06-01 2021-09 /pmc/articles/PMC8453514/ /pubmed/33960542 http://dx.doi.org/10.1002/pds.5263 Text en © 2021 Pfizer Inc. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
de Luise, Cynthia
Sugiyama, Naonobu
Morishima, Toshitaka
Higuchi, Takakazu
Katayama, Kayoko
Nakamura, Sho
Chen, Haoqian
Nonnenmacher, Edward
Hase, Ryota
Jinno, Sadao
Kinjo, Mitsuyo
Suzuki, Daisuke
Tanaka, Yoshiya
Setoguchi, Soko
Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study
title Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study
title_full Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study
title_fullStr Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study
title_full_unstemmed Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study
title_short Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study
title_sort validity of claims‐based algorithms for selected cancers in japan: results from the validate‐j study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453514/
https://www.ncbi.nlm.nih.gov/pubmed/33960542
http://dx.doi.org/10.1002/pds.5263
work_keys_str_mv AT deluisecynthia validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy
AT sugiyamanaonobu validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy
AT morishimatoshitaka validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy
AT higuchitakakazu validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy
AT katayamakayoko validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy
AT nakamurasho validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy
AT chenhaoqian validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy
AT nonnenmacheredward validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy
AT haseryota validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy
AT jinnosadao validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy
AT kinjomitsuyo validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy
AT suzukidaisuke validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy
AT tanakayoshiya validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy
AT setoguchisoko validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy